Can-Fite Shares Surge After Pancreatic Cancer Study Showed Durable Survival Outcomes

MT Newswires Live01:11

Can-Fite BioPharma (CANF) shares jumped 43% in Wednesday trading after the company said its phase 2a study of Namodenoson in advanced pancreatic cancer met its primary safety endpoint and showed durable survival in a subset of heavily pretreated patients.

The open-label trial enrolled 20 patients with advanced pancreatic ductal adenocarcinoma, an aggressive form of pancreatic cancer, who had progressed after standard treatment, according to a statement.

Among eight evaluable patients treated as third-line therapy who survived at least two months after treatment initiation, median overall survival exceeded five months, with 37.5% surviving seven months or longer, according to the company.

Can-Fite said it plans to advance Namodenoson into a Phase 2b study combining it with chemotherapy.

Price: 4.24, Change: +1.27, Percent Change: +42.76

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2648816540?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-02 01:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2648816540","market":"nz","top_or_hot":-1,"title":"Can-Fite Shares Surge After Pancreatic Cancer Study Showed Durable Survival Outcomes","media":"MT Newswires Live","content":"<html><body><p> Can-Fite BioPharma (CANF) shares jumped 43% in Wednesday trading after the company said its phase 2a study of Namodenoson in advanced pancreatic cancer met its primary safety endpoint and showed durable survival in a subset of heavily pretreated patients.</p><p>The open-label trial enrolled 20 patients with advanced pancreatic ductal adenocarcinoma, an aggressive form of pancreatic cancer, who had progressed after standard treatment, according to a statement.</p><p>Among eight evaluable patients treated as third-line therapy who survived at least two months after treatment initiation, median overall survival exceeded five months, with 37.5% surviving seven months or longer, according to the company.</p><p>Can-Fite said it plans to advance Namodenoson into a Phase 2b study combining it with chemotherapy.</p><p>Price: 4.24, Change: +1.27, Percent Change: +42.76</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Can-Fite Shares Surge After Pancreatic Cancer Study Showed Durable Survival Outcomes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCan-Fite Shares Surge After Pancreatic Cancer Study Showed Durable Survival Outcomes\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-02 01:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Can-Fite BioPharma (CANF) shares jumped 43% in Wednesday trading after the company said its phase 2a study of Namodenoson in advanced pancreatic cancer met its primary safety endpoint and showed durable survival in a subset of heavily pretreated patients.</p><p>The open-label trial enrolled 20 patients with advanced pancreatic ductal adenocarcinoma, an aggressive form of pancreatic cancer, who had progressed after standard treatment, according to a statement.</p><p>Among eight evaluable patients treated as third-line therapy who survived at least two months after treatment initiation, median overall survival exceeded five months, with 37.5% surviving seven months or longer, according to the company.</p><p>Can-Fite said it plans to advance Namodenoson into a Phase 2b study combining it with chemotherapy.</p><p>Price: 4.24, Change: +1.27, Percent Change: +42.76</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CANF","symbol_name":"Can-Fite Biopharma Ltd","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2648816540","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2648816540","pubTimestamp":1782925891,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Can-Fite BioPharma (CANF) shares jumped 43% in Wednesday trading after the company said its phase 2a study of Namodenoson in advanced pancreatic cancer met its primary safety endpoint and showed durab","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CANF":"Can-Fite Biopharma Ltd","BK4139":"生物科技"},"translate_title":"胰腺癌研究显示持久生存结果后，Can-Fite股价飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CANF":1},"content_text":"Can-Fite BioPharma (CANF) shares jumped 43% in Wednesday trading after the company said its phase 2a study of Namodenoson in advanced pancreatic cancer met its primary safety endpoint and showed durable survival in a subset of heavily pretreated patients.The open-label trial enrolled 20 patients with advanced pancreatic ductal adenocarcinoma, an aggressive form of pancreatic cancer, who had progressed after standard treatment, according to a statement.Among eight evaluable patients treated as third-line therapy who survived at least two months after treatment initiation, median overall survival exceeded five months, with 37.5% surviving seven months or longer, according to the company.Can-Fite said it plans to advance Namodenoson into a Phase 2b study combining it with chemotherapy.Price: 4.24, Change: +1.27, Percent Change: +42.76","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2648816540","isCrawlerRequest":true}